Anti-human a-Synuclein mAb 10D2
α-Synuclein is a highly abundant neuronal protein (0.5–1% of total brain protein), concentrated at presynaptic terminals. It supports membrane stability, presynaptic signaling, and vesicular trafficking.
The antibody is produced exclusively from hybridoma and purified through one-step purification with Protein-A affinity chromatography.
In stock
Delivery time: 2-5 days
From: 326,00 € Excl. VAT and delivery costs
Please contact us for larger quantities.
α-Synuclein is a highly abundant neuronal protein (0.5–1% of total brain protein), concentrated at presynaptic terminals. It supports membrane stability, presynaptic signaling, and vesicular trafficking. In its normal state, α-synuclein is a small, soluble protein that associates with phospholipid membranes, adopting an amphipathic α-helical structure upon lipid binding. Under pathological conditions, however, it is highly increased and adopts a neurotoxic β-sheet conformation, driving aggregation, fibril formation, and deposition in Lewy bodies, which are a hallmark of Parkinson's disease and other synucleinopathies. These misfolded aggregates are thought to disrupt cellular processes and contribute to neuronal dysfunction and death.
The clone 10D2 is a Monoclonal Mouse antibody against Human human a-Synuclein, SNCA (Uniprot: H6UYS7).
The antibody is produced exclusively from hybridoma and purified through one-step purification with Protein-A affinity chromatography.
| Product-ID: | INV4000049 |
|---|---|
| Clone: | 10D2 |
| Immunogen: | Animals were immunized with recombinant human a-Synuclein |
| Host: | Mouse |
| Clonality: | Monoclonal |
| Isotype: | IgG1k |
| Formulation: | Clear Liquid, PBS, pH 7.4 |
| Concentration: | > 1.0 mg/ml |
| Purity: | > 95% by SDS-PAGE |
| Sizes available: | 0.1 mg and 1.0 mg |
| Storage: | at - 20 °C (repeated thawing and freezing should be avoided) |
| Tested application(s): | ELISA, Western Blot, Immunhistochemistry |
The product is for research use only and not for use in diagnostic or therapeutic procedures.
Additional information
| Literature | [1] – Tofaris GK. Initiation and progression of α-synuclein pathology in Parkinson’s disease. Cell Mol Life Sci. 2022 Mar 26;79(4):210. doi: 10.1007/s00018-022-04240-2. PMID: 35347432; PMCID: PMC8960654. |
|---|---|
| Document | |
| Protocol | |
| Notice | The product is for research use only and not for use in diagnostic or therapeutic procedures. |
You must be logged in to post a review.

Reviews
There are no reviews yet.